Prolonged Erection of the Penis
Patients taking Quitapex are at an increased risk. These patients may experience prolonged erection of the penis (priapism
). Surgical procedures should be considered for the treatment of priapism.
Increased Levels of Prolactin
Patients taking Quitapex are at an increased risk. These patients may experience increased levels of prolactin, which may lead to reduced pituitary gonadotrophin secretion and ultimately reduced functioning of the reproductive system. These patients may also experience abnormal milky discharge from breasts (galactorrhea
), the absence of menstruation
), enlarged breasts in men (gynecomastia
), and erection abnormality (impotence
). Decreased bone density may occur in these patients.
Increased Levels of Liver Enzymes
Patients taking Quitapex are at an increased risk. These patients may experience increased levels of transaminases such as alanine aminotransferase.
Memory and Movement Problems
Patients taking Quitapex are at an increased risk. Quitapex may cause drowsiness, sedation, falls
, and abnormality in thinking, judgment or movements. Patients should take necessary precaution while operating
heavy machines such as automobiles.
Elderly patients, patients with a history of seizures
, condition associated with seizures, or taking Quitapex are at an increased risk. Quitapex may cause seizures in these patients. Precaution should be taken in such patients.
Elderly patients especially elderly women taking Quitapex, are at an increased risk. These patients may experience irreversible and involuntary body movements (tardive dyskinesia
). This risk increases as the treatment duration increases. Long-term antipsychotic treatment should be given in patients with serious illness. The smallest dose for the shortest duration should be used in such patients. Quitapex should be discontinued, or dose reduction should be considered in patients developing symptoms of involuntary body movements.
Low Blood Pressure on Quickly Standing
Elderly patients or patients taking Quitapex are at an increased risk. Quitapex may cause dizziness
, increased heart rate, loss of consciousness, falls
, or low blood pressure on quickly standing up in these patients in the starting period of Quitapex therapy. Precaution should be taken in patients with low blood volume, low body fluid, taking antihypertensive drugs, and in blood vessel related heart and brain diseases. Starting dose should be kept small, and dose should be increased slowly afterward. If low blood pressure still develops, then the previous dose should be considered.
Low Levels of Blood Cells
Patients with history or already low levels of white blood cells count/absolute neutrophil count, or taking Quitapex are at an increased risk. Quitapex may decrease the number of leukocytes (leukopenia), granulocytes, or neutrophils in these patients. Complete blood count test should be performed in such patients in the initial period and during drug therapy. Patients should be informed to report the doctor immediately on the occurrence of any signs of infection and low levels of granulocytes. On the occurrence of low white blood cell or neutrophil count, Quitapex should be discontinued. Patients should be monitored and treated for symptoms of infection such as fever
Cloudiness of the Lens in the Eye
Adults and children using Quitapex for long-term are at an increased risk. Long-term use of Quitapex may cause cloudiness of the lens in the eye (cataracts
) in these patients. An appropriate method such as slit lamp exam should be used for the diagnosis of the cataract in the starting and during Quitapex therapy.
Abnormal Heart Rhythm
Elderly patients, patients taking medicines known to cause electrolyte imbalance/QT prolongation, an overdose of Quitapex or with any other illness are at an increased risk. These patients may experience prolonged heartbeat (QT prolongation). Quitapex should not be used in patients with a history of abnormal heartbeat, low levels of potassium/magnesium, birth defects related to abnormal heart rhythm, or taking drugs known to cause QT prolongation such as quinidine, gatifloxacin, or methadone. Precaution should be used in patients with heart failure, thickened heart muscles (heart hypertrophy) or taking neuroleptics.
Elderly patients suffering from a mental disorder associated learning abnormality (dementia-related psychosis
) are at an increased risk when using Quitapex. These patients may experience an increased incidence of blood vessel-related brain diseases, heart failure or lung infection (pneumonia
) which can be possibly fatal. Quitapex should not be used in such patients. Take necessary precautions while using Quitapex in patients with a risk factor for stroke
Suicidal Thoughts and Behavior
Children and young adults (age 18 to 24 years) or patients with mood disorder, schizophrenia
, and depression/psychotics disorders are at an increased risk when using Quitapex. These patients may experience worsening of the depression
and suicide-related/unusual changes in behaviors such as agitation, anxiety
, panic attacks, irritability, etc. Patients should be monitored closely for suicide-related/unusual changes in behaviors in the starting of therapy or during dose adjustment. Discontinuation of Quitapex, the lowest effective dose or changes in the therapy should be considered in such patients.
Neuroleptic Malignant Syndrome
Patients taking Quitapex are at an increased risk. Drug-induced life-threatening reaction (neuroleptic malignant syndrome
) may occur in these patients and may experience symptoms such as high fever
, abnormal mental status, muscle rigidity, irregular blood pressure, abnormal heart rhythm, increased heart rate, sweating, increased creatinine
phosphokinase, kidney failure, and myoglobin in the urine. Monitoring and treatment of neuroleptic malignant syndrome, discontinuation of Quitapex or other drugs not required for the combined therapy should be considered. Antipsychotic drug therapy should be reintroduced after recovery from the neuroleptic malignant syndrome.
High Blood Sugar
Patients with high blood sugar are at an increased risk while taking Quitapex. These patients may experience an increased level of glucose and acids in the blood, weight gain, a complication of high blood sugar (diabetic hyperosmolar coma
) or fatality. These patients should be observed for symptoms of high blood sugar such as weakness, increased thirst or urine passage and excessive eating (polyphagia
). Such patients should be monitored regularly for body weight changes or worsening of sugar level. Fasting blood sugar test should be performed in the starting and during the treatment with Quitapex.
Children or patients taking Quitapex are at an increased risk. These patients may experience metabolic changes such as an increase in weight, changes in lipids
levels such as an increase in triglycerides
, total cholesterol
, high-density lipoprotein, and a decrease in high-density lipoprotein. Patients should be monitored for metabolic changes, and appropriate treatment should be used.